Drugmaker Biogen beat analysts' estimates for first-quarter on higher sales of its growth driver Spinraza.
Net income attributable to the company rose 20 percent to $1.41 billion, in the quarter ended March 31. On an adjusted basis, the company earned $6.98 per share on revenue of $3.49 billion. Analysts had expected the company to earn $6.87 per share on revenue of $3.39 billion.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.
Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
---|---|---|---|---|
BIIB | 100% | -0.61% | ||
AZN - BIIB | 34% Loosely correlated | -1.38% | ||
JNJ - BIIB | 32% Poorly correlated | -0.77% | ||
MRK - BIIB | 29% Poorly correlated | -0.54% | ||
PFE - BIIB | 29% Poorly correlated | -2.29% | ||
ABBV - BIIB | 27% Poorly correlated | -0.12% | ||
More |